Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Panos Zanos, Jaclyn N. Highland, Brent W. Stewart, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 13, pp. 6441-6450
Open Access | Times Cited: 128

Showing 1-25 of 128 citing articles:

Role of BDNF in the pathophysiology and treatment of depression: Activity‐dependent effects distinguish rapid‐acting antidepressants
Ronald S. Duman, Satoshi Deyama, Manoela V. Fogaça
European Journal of Neuroscience (2019) Vol. 53, Iss. 1, pp. 126-139
Open Access | Times Cited: 252
Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites
Chun Yang, Jianjun Yang, Ailin Luo, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 163
Ketamine: A tale of two enantiomers
Luke A. Jelen, Allan H. Young, James Stone
Journal of Psychopharmacology (2020) Vol. 35, Iss. 2, pp. 109-123
Open Access | Times Cited: 162
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Lily R. Aleksandrova, Anthony G. Phillips
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 11, pp. 929-942
Closed Access | Times Cited: 161
Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice
Mario de la Fuente Revenga, Bohan Zhu, Christopher A. Guevara, et al.
Cell Reports (2021) Vol. 37, Iss. 3, pp. 109836-109836
Open Access | Times Cited: 147
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 116
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate
CNS Drugs (2021) Vol. 35, Iss. 5, pp. 527-543
Open Access | Times Cited: 108
Experimenters’ sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor
Polymnia Georgiou, Panos Zanos, Ta-Chung M. Mou, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 9, pp. 1191-1200
Open Access | Times Cited: 99
NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine
Panos Zanos, Kyle A. Brown, Polymnia Georgiou, et al.
Journal of Neuroscience (2023) Vol. 43, Iss. 6, pp. 1038-1050
Open Access | Times Cited: 55
Ketamine in neuropsychiatric disorders: an update
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 23-40
Closed Access | Times Cited: 47
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Kyle A. Brown, Todd D. Gould
Molecular Psychiatry (2024) Vol. 29, Iss. 4, pp. 1114-1127
Open Access | Times Cited: 16
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Jaclyn N. Highland, Panos Zanos, Lace M. Riggs, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 2, pp. 763-791
Open Access | Times Cited: 75
Ketamine and the Future of Rapid-Acting Antidepressants
Lace M. Riggs, Todd D. Gould
Annual Review of Clinical Psychology (2021) Vol. 17, Iss. 1, pp. 207-231
Open Access | Times Cited: 62
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Yating Wang, Xiaole Wang, Sitong Feng, et al.
Pharmacological Research (2021) Vol. 171, pp. 105761-105761
Closed Access | Times Cited: 56
Novel Pharmacological Approaches to the Treatment of Depression
Elias Elias, Ariel Y. Zhang, Melissa T. Manners
Life (2022) Vol. 12, Iss. 2, pp. 196-196
Open Access | Times Cited: 48
Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
Songbai Xu, Xiaoxiao Yao, Bingjin Li, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 38
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
A new module in the drug development process: preclinical multi-center randomized controlled trial of R-ketamine on alcohol relapse
Marcus W. Meinhardt, Ivan Skorodumov, Jérôme Jeanblanc, et al.
Neuropsychopharmacology (2025)
Open Access | Times Cited: 1
mGlu2 and mGlu3 Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like Effects
Max E. Joffe, Chiaki I. Santiago, Kendra H. Oliver, et al.
Neuron (2019) Vol. 105, Iss. 1, pp. 46-59.e3
Open Access | Times Cited: 71
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
Cristan Farmer, Jessica R. Gilbert, Ruin Moaddel, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1398-1404
Open Access | Times Cited: 69
The influence of ketamine on drug discovery in depression
Christoph Kraus, Daniel Wasserman, Ioline D. Henter, et al.
Drug Discovery Today (2019) Vol. 24, Iss. 10, pp. 2033-2043
Open Access | Times Cited: 66
Biotransformation: Impact and Application of Metabolism in Drug Discovery
Julia Shanu-Wilson, Liam Evans, Stephen K. Wrigley, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 11, pp. 2087-2107
Open Access | Times Cited: 63
Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation
Jessica R. Gilbert, Carlos A. Zarate
Pharmacology Biochemistry and Behavior (2020) Vol. 189, pp. 172856-172856
Open Access | Times Cited: 54
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Jordi Bonaventura, Juan L. Gomez, Meghan L. Carlton, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 10, pp. 4144-4156
Open Access | Times Cited: 31
An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions
Vern Lewis, Gareth M. Rurak, Natalina Salmaso, et al.
Trends in Neurosciences (2024) Vol. 47, Iss. 3, pp. 195-208
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top